LinkedIn Profile

Access Paion AG historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:paionag 2136327 May 30th, 2019 12:00AM PAION AG 639 37.00 Open Pharmaceuticals May 30th, 2019 07:37PM May 30th, 2019 07:37PM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION has so far focused on the development of remimazolam for the indication of general anesthesia. A full clinical development program for general anesthesia was completed in Japan. In the EU, PAION initiated a Phase III trial in July 2018. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Open Open Martinstr. 10-12 Aachen DE 52062 Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 17th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 16th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 15th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 14th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 13th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 12th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 11th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 10th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology
private:paionag 2136327 Feb 9th, 2018 12:00AM PAION AG 455 28.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate which is in Phase III clinical development for use in procedural sedation in the U.S. Currently, PAION is mainly focusing its business and financial resources on successfully completing its ongoing clinical development program in procedural sedation. Outside the U.S., PAION has so far focused on the development of remimazolam in the indication general anesthesia. A full clinical development program for general anes­thesia was completed in Japan and PAION is preparing filing in Japan. In the EU, PAION is currently planning to continue the clinical development program. Development of remimazolam in the indication intensive care unit (ICU) sedation is also part of the longer term life-cycle plan for remimazolam. PAION is headquartered in Aachen (Germany) with a further site in Cambridge (United Kingdom). PAION's vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3). Paion AG Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.